Analyst Consensus ?
ConsensusHold23 ratings
Bullish1356.5%
Neutral834.8%
Bearish28.7%
Reinsurance Group of America, Incorporated · RGA · FY2025 Q1 · Calendar Q2 2025
RGA: Strong Q1 momentum, with claims and deployment risks
The supplied analysis supports a constructive but qualified view of RGA’s trajectory: favorable claims, Creation Re adoption, capital capacity and transaction opportunities support growth, while mortality volatility, investment income, execution and competitive pressures remain material checks.
Reported Before market openNYSEFinancial Services
$17.42B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $5.42
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $5.69B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-0.2%
Event window
SPY move
+0.7%
Same window
Abnormal move
-0.9%
Stock minus SPY
Volume
1.6×
Versus trailing sessions
Subsequent drift
+8.7%
Up to 20 sessions
RGASPY benchmark
Ask FN2 about RGA FY2025 Q1
Transcript, numbers and history already loaded
What drove RGA's -0.2% move after FY2025 Q1 earnings?What changed in RGA's guidance and outlook in FY2025 Q1?Give me the bull and bear case for RGA after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the supplied prior-quarter analysis, the current analysis emphasizes Q1 adjusted earnings and ROE, favorable claims across regions, Creation Re exceeding half of new business, and the planned Equitable mortality-block transaction. Guidance sentiment is maintained.
Guidance delta
Maintained; the supplied analysis does not identify a new guidance change.
Key takeaways
- Management described favorable biometric claims experience across regions as a driver of Q1 profitability.
- The Creation Re model accounted for more than half of new business in the supplied analysis.
- The supplied analysis highlighted $1.3 billion of deployable capital and a pipeline spanning Asia, Japan, and the U.S.
- The Equitable mortality-block transaction was presented as a way to improve ROE and diversify the mortality portfolio.
Management priorities
- Close the Equitable transaction by mid-year 2025
- Scale the Creation Re model across regions
- Pursue block transactions in Japan and other Asian markets
- Deploy excess capital into private assets and strategic retrocession structures
- Advance in-force management actions to enhance ROE over time
Follow RGA with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$266.75Current
$141Low
$225.33Average
$295High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 18, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Overweight | Overweight | Maintain | Oct 15, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Oct 12, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 8, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Aug 24, 2026 |
| TD Cowen | Hold | Hold | Maintain | Jul 22, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 13, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 8, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | May 11, 2026 |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Nov 3, 2025 |
| Raymond James | Underperform | Market Perform | Downgrade | Oct 17, 2025 |
| RBC Capital | Outperform | Outperform | Maintain | Feb 10, 2025 |
| Citigroup | Buy | Buy | Maintain | Jul 23, 2024 |
| Jefferies | Buy | Buy | Maintain | Jul 10, 2024 |
| Credit Suisse | Neutral | Neutral | Maintain | May 24, 2023 |
| Goldman Sachs | Buy | Buy | Maintain | Jan 9, 2023 |
| Wolfe Research | Underperform | Underperform | Maintain | Jan 21, 2022 |
| Keefe Bruyette & Woods | Outperform | Market Perform | Upgrade | Jul 30, 2018 |
| Deutsche Bank | Hold | Buy | Downgrade | Oct 19, 2016 |
| Macquarie | Outperform | Outperform | Maintain | Nov 4, 2015 |
| PiperJaffray | Neutral | Neutral | Maintain | Oct 30, 2015 |
| Keefe, Bruyette& Woods | Market Perform | Market Perform | Maintain | Dec 30, 2014 |
| Sterne Agee | Neutral | Neutral | Maintain | Jul 17, 2014 |
| Evercore Partners | Overweight | Equal Weight | Upgrade | Dec 19, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $266.75. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $292 | $251.53 | +9.5% | Oct 8, 2026 |
| Barclays | Analyst unavailable | $286 | $251.14 | +7.2% | Oct 7, 2026 |
| Morgan Stanley | Analyst unavailable | $295 | $252.84 | +10.6% | Sep 28, 2026 |
| Morgan Stanley | Analyst unavailable | $250 | $245.4 | -6.3% | Aug 24, 2026 |
| Wells Fargo | Analyst unavailable | $291 | $244.42 | +9.1% | Aug 19, 2026 |
| Barclays | Analyst unavailable | $290 | $236.31 | +8.7% | Aug 7, 2026 |
| UBS | Analyst unavailable | $236 | $232.3 | -11.5% | Jul 8, 2026 |
| Barclays | Analyst unavailable | $278 | $224.08 | +4.2% | Jul 7, 2026 |
| Evercore ISI | Analyst unavailable | $267 | $215.21 | +0.1% | May 18, 2026 |
| Piper Sandler | Analyst unavailable | $261 | $210.6 | -2.2% | May 11, 2026 |
| Barclays | Analyst unavailable | $268 | $212.81 | +0.5% | May 8, 2026 |
| UBS | Analyst unavailable | $220 | $208.8 | -17.5% | Apr 9, 2026 |
| Piper Sandler | Analyst unavailable | $263 | $227.7 | -1.4% | Feb 6, 2026 |
| Barclays | Analyst unavailable | $245 | $205.99 | -8.2% | Feb 6, 2026 |
| Wells Fargo | Analyst unavailable | $238 | $202.13 | -10.8% | Jan 13, 2026 |
| Barclays | Analyst unavailable | $237 | $201.04 | -11.2% | Jan 8, 2026 |
| Piper Sandler | John Barnidge | $230 | $207.02 | -13.8% | Dec 23, 2025 |
| Morgan Stanley | Bob Huang | $208 | $205.03 | -22.0% | Dec 15, 2025 |
| Morgan Stanley | Bob Huang | $195 | $187.14 | -26.9% | Aug 18, 2025 |
| Morgan Stanley | Bob Huang | $209 | $209.71 | -21.6% | May 19, 2025 |
| UBS | Michael Ward | $216 | $199.96 | -19.0% | Apr 2, 2025 |
| Morgan Stanley | Analyst unavailable | $224 | $202.69 | -16.0% | Feb 28, 2025 |
| Barclays | Alex Scott | $255 | $219.59 | -4.4% | Sep 4, 2024 |
| Piper Sandler | John Barnidge | $237 | $218.66 | -11.2% | Sep 4, 2024 |
| Morgan Stanley | Bob Huang | $236 | $209.36 | -11.5% | Aug 19, 2024 |
| Piper Sandler | John Barnidge | $228 | $204.37 | -14.5% | Jun 10, 2024 |
| Piper Sandler | John Barnidge | $220 | $191.35 | -17.5% | Apr 5, 2024 |
| Jefferies | Suneet Kamath | $189 | $163.64 | -29.1% | Dec 10, 2023 |
| Morgan Stanley | Analyst unavailable | $160 | $146.36 | -40.0% | Jan 10, 2023 |
| Goldman Sachs | Analyst unavailable | $162 | $146.61 | -39.3% | Jan 9, 2023 |
| J.P. Morgan | Analyst unavailable | $141 | $145.56 | -47.1% | Jan 6, 2023 |
| Evercore ISI | Thomas Gallagher | $167 | $145.11 | -37.4% | Jan 5, 2023 |
| RBC Capital | Analyst unavailable | $170 | $139.23 | -36.3% | Dec 6, 2022 |
Track every rating change on RGA the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationReinsurance Group of America, Inc. (RGA) primarily operates within the reinsurance sector. The company delivers a comprehensive portfolio of life and health reinsurance products, spanning both individual and group coverages. These include diverse life insurance options such as term, credit, universal, whole, and joint/last survivor policies, in addition to critical illness, disability, and longevity products. RGA also offers specialized asset-intensive and financial reinsurance, alongside other solutions focused on capital optimization.…
Historical context
All RGA earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| MTB-PH M&T Bank Corporation | FY2026 Q3 · Calendar Q4 2026 | +2.2% | — | M&T Bank: Loan Growth Holds Up as Rates Pressure Margins |
| MTB-PJ M&T Bank Corporation | FY2026 Q3 · Calendar Q4 2026 | +2.2% | — | M&T: Deposit growth supports margins as AI use expands |
| RF-PE Regions Financial Corporation | FY2026 Q3 · Calendar Q4 2026 | +10.3% | — | Regions Financial: Fee Growth and Credit Quality Support Q3 |
| RF-PC Regions Financial Corporation | FY2026 Q3 · Calendar Q4 2026 | +10.3% | — | Regions Financial: Fee growth supports a steady Q3 outlook |
| TFC-PI Truist Financial Corporation | FY2026 Q3 · Calendar Q4 2026 | -50.9% | — | Truist sharpens focus as Q3 EPS rises 12% |
| TRV The Travelers Companies, Inc. | FY2026 Q3 · Calendar Q4 2026 | +24.2% | +1.5% | Travelers posts strong Q3, with investment income above $900 million |
Latest beats and misses
Who reports nextBeat on EPS
Get the RGA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-17T00:02:52.217204+00:00
- Polygon adjusted daily market bars · 2026-10-18T06:30:40.866222+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-18T06:30:40.863589+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-18. For educational purposes only; not investment advice.